ライフサイエンスコーパス: occluder

1 losed using an off-the-shelf nitinol cardiac occluder.

2 as endovascularly closed using the Amplatzer occluder.

3 to the emergence of a target from behind an occluder.

4 t direction when the finger passed behind an occluder.

5 nd stenosis was achieved in the LCX with the occluder.

6 e virtual fingertip while it moved behind an occluder.

7 uccessful deployment of the Amplatzer Septal Occluder.

8 ect was then closed with an Amplatzer Septal Occluder.

9 onary artery in dogs was produced by a screw occluder.

10 cluded object appears to continue behind its occluder.

11 mm apart on the button loop attached to the occluder.

12 etion occurs when a contour passes behind an occluder.

13 nd left atrial catheters and coronary artery occluders.

14 ccess ports were closed with nitinol cardiac occluders.

15 h in CL conditions, with or without hoods or occluders.

16 our had placement of thoracic aortic balloon occluders.

17 nic lung lymph fistulas and pulmonary venous occluders.

18 ults of the multicenter USA Amplatzer ductal occluder (ADO) device trial.

19 VSDs) using the new Amplatzer Membranous VSD Occluder (AGA Medical Corp., Golden Valley, Minnesota) i

20 defects (VSDs) using the new Amplatzer mVSD occluder (AGA Medical Corp., Golden Valley, Minnesota).

21 sachusetts] and Amplatzer PFO Occluder [disc occluder] [AGA Medical/St. Jude Medical, St. Paul, Minne

22 dogs was encircled (day 0) with a hydraulic occluder and ameroid constrictor to enable reversible an

23 lly instrumented with a reversible hydraulic occluder and Doppler flowmeter to study RII (n = 8).

24 Eighteen swine with a hydraulic occluder and flow probe on the circumflex artery underwe

25 ry artery stenosis was induced by an ameroid occluder and maintained for 1 or 2 weeks (end point) in

26 In several active conditions, the spot, occluder and shape translated such that when subjects tr

27 o 5 minutes later followed by release of the occluders and rewarming.

28 umented with a Doppler flow probe, hydraulic occluder, and indwelling catheter on the left anterior d

29 ted with a Doppler velocity probe, hydraulic occluder, and indwelling microcatheter in the left anter

30 12 dogs was instrumented with a flow probe, occluder, and intracoronary pressure catheter, and non-f

31 atrial septal defect devices, patent ductus occluders, and stents to treat coarctation of the aorta.

32 ed by the intersection of the object and the occluder are generally not consistent with the direction

33 of transcatheter atrial septal defect (ASD) occluders are currently in use around the world.

34 were chronically instrumented with a balloon occluder around a branch of the left coronary artery and

35 zed and fitted with an extravascular balloon occluder around the brachiocephalic artery using aseptic

36 terization and implantation of extravascular occluder around the brachiocephalic artery.

37 od flow was controlled by use of a hydraulic occluder around the left iliac artery.

38 , and 9 months after placement of an ameroid occluder around the proximal left circumflex coronary ar

39 and clinical utility of the Amplatzer septal occluder (ASO) for closure of secundum atrial septal def

40 l after ASD closure with an Amplatzer septal occluder (cases) were compared with controls (matched 2:

41 automated servo-controlled inflation of the occluder cuff (n = 8).

42 ion (term is ca 145 days) with an inflatable occluder cuff around the umbilical cord, amniotic and fe

43 Automated servo-controlled inflation of the occluder cuff, programmed to reduce umbilical blood flow

44 erapy and PFO closure with the Amplatzer PFO Occluder device (St.

45 The HSO is a low-profile, double-disk occluder device for percutaneous closure of secundum ASD

46 balloon-sized ASD diameter, Amplatzer septal occluder device size, and device size-ASD diameter diffe

47 In analyses limited to the 2 disc occluder device trials, the effect of closure was not si

48 after ASD closure with the Amplatzer septal occluder device.

49 SD device closure by the new DAS-Angel Wings occluder device.

50 nt of septal communications using either new occluder devices or novel techniques.

51 c., Boston, Massachusetts] and Amplatzer PFO Occluder [disc occluder] [AGA Medical/St. Jude Medical,

52 g before, during, and after inflation of the occluder for 15 minutes was 35+/-5%, 1+/-8%, and 21+/-10

53 ision deprived in one eye with a translucent occluder for 5 days.

54 ulticenter Pivotal Study of the HELEX Septal Occluder for Percutaneous Closure of Secundum Atrial Sep

55 patients implanted with the AMPLATZER Septal Occluder for percutaneous closure of secundum atrial sep

56 old chicks by the application of translucent occluders for 10 days and was followed by unrestricted v

57 sure catheters and inferior vena caval (IVC) occluders; four had placement of thoracic aortic balloon

58 The Clamshell Septal Occluder has been used to close various congenital heart

59 the safety and efficacy of the HELEX septal occluder (HSO) with surgical repair of atrial septal def

60 examine the effectiveness and safety of this occluder in an animal model.

61 ty and effectiveness of the AMPLATZER Septal Occluder in clinical practice are not available.

62 The Helex septal occluder is a new type of device designed to improve the

63 tal defects (ASD) using the Amplatzer septal occluder is generally safe and effective, but erosion in

64 cluding material, although these fail if the occluder is opaque.

65 Closure of ASD with the HELEX septal occluder is safe and effective when compared with surgic

66 rial septal defect with the AMPLATZER Septal Occluder is safe and effective.

67 The Bard Clamshell Septal Occluder is well tolerated in the canine heart for at le

68 ith a coronary artery BF probe and hydraulic occluder, left ventricular (LV) pressure gauge, and wall

69 right atrial catheter in animals with an LCx occluder (n=2).

70 cluded data on 2 devices (STARFlex [umbrella occluder] [NMT Medical, Inc., Boston, Massachusetts] and

71 otid occlusion was elicited with a hydraulic occluder on the common carotid artery.

72 Twenty-eight weeks later, we placed an occluder on the descending thoracic aorta and inferior v

73 from rising during air breathing by using an occluder on the dorsal aorta.

74 ally instrumented pigs (n = 18) with a fixed occluder on the proximal left anterior descending corona

75 Hydraulic occluders on the thoracic aorta and inferior vena cava w

76 patent foramen ovale with the Amplatzer PFO Occluder or to receive medical therapy.

77 additional group was raised with opaque eye occluders over the right eye for 12 hours daily.

78 regional coronary occlusion using an ameroid occluder placed around the left anterior descending coro

79 The Helex septal occluder proved safe and effective for ASD closure.

80 eye growth: form deprivation by translucent occluders, spherical defocus by -10- or +10-D lenses, an

81 nal transducer to activate the putative pore-occluder, the alpha(1C) I-II intracellular linker.

82 article include the angled Amplatzer Ductal Occluder, the cribriform atrial septal defect device for

83 was surgically instrumented with an ameroid occluder to induce CCO; 8 weeks after surgery, animals w

84 ith Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management [PREMIUM]; NCT00355056).

85 ith Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management) was a double-blind study

86 By graded inflation of the occluder to produce a wide range of coronary stenosis se

87 re products available such as e.g. Amplatzer occluder to simplify the procedure and shorten the durat

88 ccluding one eye for 24 hours, switching the occluder to the fellow eye for the next 24 hours, and re

89 mplications, using permeable nitinol cardiac occluders to close the access ports, were common but acc

90 perseded the previously popular Rashkind PDA occluder (USCI/Bard, Tewksbury, MA) because of significa

91 tal defect closure with the AMPLATZER Septal Occluder was attempted in 1000 patients (aged 0.3-83.6 y

92 In 11 pigs, a hydraulic occluder was inflated distal to the flow probe.

93 The hydraulic occluder was inflated to induce a stable 41+/-4% reducti

94 A vascular occluder was inserted in 34 pigs, and they were assigned

95 used as sham-operated controls in which the occluder was not inflated throughout the protocol.

96 A hydraulic occluder was placed in the left circumflex coronary arte

97 A vascular occluder was positioned distal to the flow probe for flo

98 The occluder was then deflated allowing return of umbilical

99 One hour later, the occluder was withdrawn, and reperfusion was maintained f

100 riving pressure was altered by inflating the occluders while adenosine was infused into the left atri

101 s (access and closure with a nitinol cardiac occluder without death or emergency surgical rescue) occ